Clinical Trials Browser

Completed × Carcinoma × Pemetrexed × Clear all

NCT03976323 2026-02-25

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Phase 3 Completed

1,003 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma

NCT02185690 2025-08-21

MEK162

Phase 1 Completed

13 enrolled 11 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02367781 2021-08-09

IMpower130

Phase 3 Completed

723 enrolled 28 charts 1 FDA

Carcinoma

NCT02259582 2020-09-09

DENALI

Phase 2 Completed

82 enrolled 10 charts

Carcinoma, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00506051 2016-08-25

ZD6474(Vandetanib) + Alimta Combo Study

Phase 1 Completed

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00589667 2014-04-02

A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC)

Phase 2 Completed

26 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Head and Neck Neoplasms, Laryngeal Diseases

NCT00191308 2011-10-21

Molecular Profiling in Lung Cancer Patients

Phase 2 Completed

30 enrolled 11 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung